Establishing first protocols for Alzheimer’s blood test
To achieve FDA approval of the first blood test for early detection of Alzheimer’s disease, UNT Health Science Center Associate Professor of Internal Medicine Sid O’Bryant has created an international working group to establish standards for blood collection.
O’Bryant, who has led development of the blood test at the Health Science Center in collaboration with the Texas Alzheimer’s Research and Care Consortium (TARCC), is working with representatives from across the U.S., as well as Australia, Germany, England and Italy to develop standards for Alzheimer’s research aimed at identifying blood-based disease markers. The working group, STandards for Alzheimer’s Research in Blood biomarkers (STAR-B), represents the first initiative for creating global standards for blood collection in Alzheimer’s analysis.
In addition, the collaborators are working to establish consensus on the data that must be presented in published work to ensure the ability to cross-validate results.
While international standard protocols for spinal puncture and brain MRI in Alzheimer’s research are either available or very far in their progress, no such protocols exist for drawing blood, handling blood samples or assaying blood samples relating to Alzheimer’s research. Just as with blood tests for diabetes or any other condition, such standards must be established before FDA approval can be sought for the test to be used clinically.
“We have to standardize the procedure, from the type of needle to the type of tube used to draw blood, the length of storage time, and whether the patient fasted or not,” explained O’Bryant. “Without these standards, we can’t progress to the next step of human clinical trials of the blood test.”
The standardization effort supports O’Bryant’s quest to use a blood test as a less invasive procedure to detect Alzheimer’s disease earlier on in its progression. Earlier detection and treatment can protect the brain from further degeneration. The availability of blood-based tools could save millions of dollars in drug trial screening and patient selection costs.
O’Bryant kicked off the STAR-B collaborative effort in 2011. “It’s a long process,” O’Bryant said. “Researchers have been working for over 10 years to get international standards in place and FDA approval for a lumbar puncture test for Alzheimer’s. We hope to establish protocols and seek FDA approval on our blood test within five years.”
By Steven Bartolotta In 2007, TCOM’s Dr. Rita Patterson and Dr. Jennifer Wayne, a professor at Virginia Tech, recognized the need for women in the field of bioengineering to meet together, network, mentor and increase the representation of women in the field. Thus the ASME Bioengineering...Read more
Jun 23, 2021
A growing trove of data to help scientists understand the biology of Alzheimer’s disease among diverse populations within the context of sociocultural, behavioral and environmental factors is now available through the Institute for Translational Research at The University of North Te...Read more
Jun 22, 2021
By Diane Smith-Pinckney The embroidery on Vic Holmes’ black scrubs identify him as a physician assistant and an ally to LGBTQ+ patients. The words, stitched under a rainbow-colored Caduceus pin and near his heart, read: “Vic Holmes, PA-C, He/Him/His, Family Medicine.” Pronouns are...Read more
Jun 21, 2021
By Sally Crocker Katie Pelch, PhD, wants you to know what’s in our environment and how the chemicals we’re exposed to every day may affect our health. Dr. Pelch is a part-time Assistant Professor, Department of Biostatistics and Epidemiology, in the HSC School of Public Health (SPH), where...Read more
Jun 21, 2021